- Home
- WLGS vs CVKD Comparison
WLGS vs CVKD Comparison
Compare WLGS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- CVKD
- Stock Information
- Founded
- WLGS 1981
- CVKD 2022
- Country
- WLGS Hong Kong
- CVKD United States
- Employees
- WLGS N/A
- CVKD N/A
- Industry
- WLGS Engineering & Construction
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- WLGS Consumer Discretionary
- CVKD Health Care
- Exchange
- WLGS Nasdaq
- CVKD Nasdaq
- Market Cap
- WLGS 22.2M
- CVKD 17.1M
- IPO Year
- WLGS 2023
- CVKD 2023
- Fundamental
- Price
- WLGS $2.58
- CVKD $14.45
- Analyst Decision
- WLGS
- CVKD Strong Buy
- Analyst Count
- WLGS 0
- CVKD 2
- Target Price
- WLGS N/A
- CVKD $52.50
- AVG Volume (30 Days)
- WLGS 269.6K
- CVKD 59.6K
- Earning Date
- WLGS 11-14-2024
- CVKD 11-08-2024
- Dividend Yield
- WLGS N/A
- CVKD N/A
- EPS Growth
- WLGS N/A
- CVKD N/A
- EPS
- WLGS N/A
- CVKD N/A
- Revenue
- WLGS $6,825,879.00
- CVKD N/A
- Revenue This Year
- WLGS N/A
- CVKD N/A
- Revenue Next Year
- WLGS N/A
- CVKD N/A
- P/E Ratio
- WLGS N/A
- CVKD N/A
- Revenue Growth
- WLGS 63.69
- CVKD N/A
- 52 Week Low
- WLGS $0.40
- CVKD $5.40
- 52 Week High
- WLGS $4.20
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- WLGS 58.66
- CVKD 56.80
- Support Level
- WLGS $2.33
- CVKD $11.19
- Resistance Level
- WLGS $4.20
- CVKD $17.95
- Average True Range (ATR)
- WLGS 0.65
- CVKD 1.37
- MACD
- WLGS 0.04
- CVKD 0.10
- Stochastic Oscillator
- WLGS 34.29
- CVKD 49.64
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.